Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Assertio Holdings
ASRT
Assertio Holdings
Rising Pricing Pressures And Portfolio Exposure Will Test Future Recoveries
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.50
47.9% undervalued
intrinsic discount
25 Aug
US$0.78
1Y
-35.5%
7D
-0.5%
Loading
1Y
-35.5%
7D
-0.5%
Author's Valuation
US$1.5
47.9% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.5
47.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-196m
443m
2014
2017
2020
2023
2025
2026
2028
Revenue US$136.8m
Earnings US$10.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.08%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$10.79m
Earnings '28
x
16.59x
PE Ratio '28
=
US$178.95m
Market Cap '28
US$178.95m
Market Cap '28
/
98.56m
No. shares '28
=
US$1.82
Share Price '28
US$1.82
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$1.49
Fair Value '25
